山东东方海洋科技股份有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002086 证券简称：东方海洋 公告编号：2026-002 诉讼进展公告 本公司及董事会全体成员保证信息披露的真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1．案件所处的诉讼阶段：第一批投资者诉讼案件其中4名原告（綦领颜、王玲丽、王艳芳、张晖）案件 重一审判决。 2．上市公司所处的当事人地位：被告。 3．涉案的金额：4名原告合计对被告公司享有31,128,243.49元债权以及被告公司合计负担案件受理费 265,030元。 4．是否会对上市公司损益产生负面影响：公司前期已根据原审判决情况计提预计负债，对公司本期利 润或期后利润无重大影响。公司将持续密切关注案件后续进展，并严格按照相关规定及时履行信息披露 义务。 71,910元予以退回。《民事裁定书》【（2025）鲁民终178号】裁定如下：一、撤销青岛中院 【（2023）鲁02民初1163号】民事判决；二、本案发回青岛中院重审。公司预交的二审案件受理费 79,799元予以退回。《民事裁定书》【（2025）鲁民终179号】裁定如下：一、撤销青岛中院 【 ...

证券代码：002086 证券简称：东方海洋 公告编号：2026-002 山东东方海洋科技股份有限公司 诉讼进展公告 本公司及董事会全体成员保证信息披露的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 特别提示 1．案件所处的诉讼阶段：第一批投资者诉讼案件其中4名原告（綦领颜、王玲丽、 王艳芳、张晖）案件重一审判决。 2．上市公司所处的当事人地位：被告。 3．涉案的金额：4名原告合计对被告公司享有31,128,243.49元债权以及被告公司 合计负担案件受理费265,030元。 4．是否会对上市公司损益产生负面影响：公司前期已根据原审判决情况计提预 计负债，对公司本期利润或期后利润无重大影响。公司将持续密切关注案件后续进展， 并严格按照相关规定及时履行信息披露义务。 一、第一批投资者诉讼案件 1．案件基本情况概述 山东东方海洋科技股份有限公司（以下简称"公司"）因涉嫌信息披露违法违规于 2019 年 9 月 27 日收到中国证券监督管理委员会山东监管局下发的《行政处罚决定书》 （【2019】9 号），部分中小投资者以"证券虚假陈述责任纠纷"为由向法院提起民事 诉讼。公司于 2025 年 4 月 2 ...

Core Viewpoint - The company is involved in a lawsuit with four plaintiffs who collectively hold a debt claim of 31.1282 million yuan against the company, with the company responsible for a case acceptance fee of 265,000 yuan [1] Group 1 - The lawsuit involves four plaintiffs: Qi Lingyan, Wang Lingli, Wang Yanfang, and Zhang Hui [1] - The company has previously recognized a provision for liabilities based on the original trial judgment, indicating that the current and future profits will not be significantly impacted [1] - The company will continue to monitor the progress of the case and fulfill its information disclosure obligations in a timely manner [1]

Group 1 - The core viewpoint emphasizes the importance of collaboration between government and courts to enhance social governance efficiency in Shandong Province [2][3] - A new mechanism for regular collaboration between government and courts has been established, covering provincial, municipal, and county levels [2][3] - The first coordination meeting led to the successful restructuring of a listed company, resolving over 3 billion yuan in debts and stabilizing over 1,000 related employees [3][4] Group 2 - The collaboration has resulted in significant achievements, such as the successful mediation of 1,500 cases in the construction sector, saving 60 million yuan in litigation costs [5] - The initiative aims to transform individual case rulings into broader regulatory frameworks, enhancing overall governance effectiveness [5][6] - The establishment of a judicial recommendation for the development of offshore ranching has facilitated the creation of inspection standards and legislative plans [6] Group 3 - Future efforts will focus on addressing deeper institutional challenges, leveraging the strengths of both administrative and judicial bodies for mutual benefit [7][8] - Data sharing between government and judicial entities is identified as a critical area for further collaboration [8] - The initiative has contributed to a decrease in administrative litigation cases, indicating improved awareness and capability in lawful governance [9]

每经AI快讯，1月21日，东方海洋公告，全资子公司艾维可生物科技有限公司收到国家药品监督管理局 的医疗器械注册证，其自主研发的幽门螺杆菌（HP）抗原检测试剂盒（胶体金法）获准上市，适用于 体外定性检测人粪便样本中的幽门螺杆菌抗原。上述产品获准上市进一步丰富了艾维可生物科技有限公 司在临床检测领域的产品线。但鉴于艾维可生物科技有限公司今年对公司的业绩影响较小，本次获批产 品的投产及对公司业绩的后续影响具有不确定性。产品获证后还未投入生产，实际销售情况受市场拓展 力度及市场实际需求等多重因素影响，目前尚无法预测其对公司未来业绩的具体影响，请广大投资者注 意投资风险。 ...

东方海洋1月21日公告，公司全资子公司艾维可生物科技有限公司幽门螺杆菌抗原 检测试剂盒获得国家 药品监督管理局颁发的 医疗器械注册证。本试剂盒用于体外定性检测人粪便样本中的幽门螺杆菌抗 原。上述产品获准上市，进一步丰富了艾维可生物科技有限公司在临床检测领域的产品线。但鉴于艾维 可生物科技有限公司今年对公司的业绩影响较小，上述产品的投产以及对公司业绩的后续影响具有不确 定性。同时，上述产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场实际需求等多重因 素影响，目前尚无法预测上述产品对公司未来业绩的具体影响。 ...

证券代码：002086 证券简称：东方海洋 公告编号：2026-001 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述获批产品对公司未来业绩的具体 影响，请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的幽门螺杆菌（HP）抗原检测试剂盒（胶体金法）于近 日取得了国家药品监督管理局的注册批准，获得医疗器械注册证，具体情况如下： 一、产品信息 1、幽门螺杆菌（HP）抗原检测试剂盒（胶体金法） | 产品名称 | 幽门螺杆菌（HP）抗原检测试剂盒（胶体金法） | | | | | --- | --- | --- | --- | --- | | 注册证编号 | 国械注准 20263400136 | | | | | 注册人名称 | ...

东方海洋1月21日公告，公司全资子公司艾维可生物科技有限公司幽门螺杆菌（HP）抗原检测试剂盒 （胶体金法）获得国家药品监督管理局颁发的医疗器械注册证。本试剂盒用于体外定性检测人粪便样本 中的幽门螺杆菌抗原。上述产品获准上市，进一步丰富了艾维可生物科技有限公司在临床检测领域的产 品线。但鉴于艾维可生物科技有限公司今年对公司的业绩影响较小，上述产品的投产以及对公司业绩的 后续影响具有不确定性。同时，上述产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述产品对公司未来业绩的具体影响。 ...

证券日报网讯1月5日，东方海洋（002086）在互动平台回答投资者提问时表示，公司严格按照法律法规 及监管要求及时进行信息披露，不存在应披露而未披露的信息。 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]